Inhibition of Cell Proliferation, Vascular Endothelial Growth Factor and Tumor Growth by Albendazole

被引：28

作者：

Pourgholami, Mohammad Hossein ^{[1
]}

Cai, Zhao Yan ^{[1
]}

Wang, Lisa ^{[1
]}

Badar, Samina ^{[1
]}

Links, Matthew ^{[2
]}

Morris, David Lawson ^{[1
]}

机构：

[1] Univ New S Wales, Canc Res Labs, Dept Surg, St George Hosp SESIAHS, Sydney, NSW 2217, Australia

[2] Univ New S Wales, Dept Surg, St George Hosp SESIAHS, Canc Care Ctr, Sydney, NSW 2217, Australia

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 02期

关键词：

Albendazole; Angiogenesis; Microtubule; Ovarian cancer; OVCAR-3; VEGF; HUMAN OVARIAN-CARCINOMA; NUDE-MICE; IN-VITRO; THERAPEUTIC TARGET; KINASE INHIBITORS; MALIGNANT ASCITES; POTENT INHIBITOR; CANCER; VEGF; ANGIOGENESIS;

D O I：

10.1080/07357900802210752

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vascular endothelial growth factor (VEGF) is the key molecule mediating tumor growth and malignant ascites formation. We recently reported that, in an end stage OVCAR-3 xenograft model, albendazole (ABZ) suppresses ascites formation, but not tumor growth. Hence, in the present study, we assessed the effect of ABZ on in vitro OVCAR-3 cell proliferation plus in vivo tumor growth, however, initiating ABZ treatment at mid stage (3 weeks post cell inoculation) rather than end stage disease. Here, ABZ treatment led to potent inhibition of cell proliferation, VEGF suppression, complete inhibition of ascites formation and most strikingly arrest of tumor growth.

引用

页码：171 / 177

页数：7